Index -
P/E 1171.44
EPS (ttm) 0.18
Insider Own 1.96%
Shs Outstand 29.56M
Perf Week 4.34%
Market Cap 6.35B
Forward P/E 152.66
EPS next Y 1.39
Insider Trans -13.00%
Shs Float 29.24M
Perf Month 13.62%
Income 6.01M
PEG -
EPS next Q 0.07
Inst Own 106.13%
Short Float 4.45%
Perf Quarter 31.02%
Sales 705.71M
P/S 8.99
EPS this Y 203.56%
Inst Trans 2.59%
Short Ratio 2.01
Perf Half Y 9.03%
Book/sh 21.41
P/B 9.94
EPS next Y 86.98%
ROA 0.89%
Short Interest 1.30M
Perf Year 6.53%
Cash/sh 14.74
P/C 14.44
EPS next 5Y -
ROE 1.03%
52W Range 123.00 - 257.40
Perf YTD 4.63%
Dividend Est. -
P/FCF -
EPS past 5Y 13.57%
ROI 0.91%
52W High -17.31%
Beta 1.34
Dividend TTM -
Quick Ratio 8.35
Sales past 5Y 66.60%
Gross Margin 84.83%
52W Low 73.05%
ATR (14) 8.93
Dividend Ex-Date -
Current Ratio 9.25
EPS Y/Y TTM 114.08%
Oper. Margin -2.03%
RSI (14) 68.17
Volatility 4.42% 4.10%
Employees 1011
Debt/Eq 0.04
Sales Y/Y TTM 34.14%
Profit Margin 0.85%
Recom 1.75
Target Price 226.38
Option/Short Yes / Yes
LT Debt/Eq 0.04
EPS Q/Q 178.75%
Payout -
Rel Volume 8.68
Prev Close 212.10
Sales Surprise 3.60%
EPS Surprise 328.90%
Sales Q/Q 29.65%
Earnings Aug 06 AMC
Avg Volume 646.26K
Price 212.85
SMA20 7.96%
SMA50 22.25%
SMA200 15.10%
Trades
Volume 5,609,049
Change 0.35%
Date
Action
Analyst
Rating Change
Price Target Change
May-08-24 Downgrade
BofA Securities
Buy → Neutral
$265 → $225
Apr-19-24 Initiated
RBC Capital Mkts
Outperform
$285
Mar-19-24 Initiated
Morgan Stanley
Overweight
$250
Feb-06-24 Resumed
KeyBanc Capital Markets
Overweight
$278
Jan-19-24 Initiated
Jefferies
Buy
$245
Jan-02-24 Downgrade
Stifel
Buy → Hold
$210
Dec-13-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$245 → $187
Jul-19-23 Initiated
Robert W. Baird
Outperform
$371
Apr-14-23 Initiated
Mizuho
Buy
$300
Mar-29-23 Initiated
UBS
Buy
$300
Dec-13-22 Upgrade
Goldman
Neutral → Buy
$245 → $308
Dec-13-22 Initiated
KeyBanc Capital Markets
Overweight
$287
Apr-13-22 Initiated
Truist
Buy
$315
Apr-06-22 Initiated
Wolfe Research
Peer Perform
$270
Mar-02-22 Resumed
BofA Securities
Buy
$270
Jan-04-21 Downgrade
BofA Securities
Buy → Neutral
Dec-15-20 Downgrade
Goldman
Buy → Neutral
$162 → $209
Nov-03-20 Upgrade
Oppenheimer
Underperform → Perform
Nov-03-20 Upgrade
BofA Securities
Neutral → Buy
$125 → $155
Sep-22-20 Initiated
JP Morgan
Overweight
$148
Show Previous Ratings
Sep-18-24 09:50AM
Sep-06-24 06:43PM
Sep-02-24 09:50AM
Aug-23-24 07:35AM
Aug-21-24 04:02PM
12:20PM
Loading…
Aug-09-24 12:20PM
Aug-07-24 10:48AM
Aug-06-24 06:30PM
05:35PM
04:02PM
04:02PM
Aug-05-24 10:10AM
09:16AM
Aug-02-24 08:00AM
Jul-29-24 10:59AM
09:21AM
Loading…
09:21AM
06:45AM
Jul-23-24 08:00AM
Jul-22-24 11:35AM
08:39AM
08:00AM
04:52AM
Jul-19-24 08:00AM
08:00AM
Jul-13-24 08:36AM
Jul-10-24 11:08AM
Jul-09-24 03:17PM
Jul-02-24 08:00AM
Jun-25-24 08:30AM
Jun-24-24 04:10PM
(Investor's Business Daily) -16.72%
02:01PM
Loading…
02:01PM
10:08AM
(The Wall Street Journal)
Jun-06-24 11:31AM
Jun-04-24 08:00AM
May-28-24 06:00AM
May-23-24 08:00AM
May-21-24 12:40PM
May-09-24 09:35AM
May-08-24 01:49PM
11:33AM
10:16AM
(Thomson Reuters StreetEvents)
09:30AM
07:31AM
May-07-24 08:59PM
05:46PM
05:10PM
04:02PM
May-03-24 09:15AM
Apr-30-24 06:15PM
03:39PM
(Investor's Business Daily)
08:00AM
Apr-26-24 09:14AM
Apr-18-24 12:17PM
02:14AM
Apr-17-24 08:38AM
(The Wall Street Journal) +9.87%
Apr-08-24 05:17AM
Apr-02-24 08:00AM
Mar-27-24 07:00PM
Mar-21-24 02:31AM
Mar-18-24 12:01PM
Mar-14-24 01:49AM
Mar-05-24 08:00AM
Feb-13-24 09:02AM
05:45AM
Feb-07-24 11:33AM
(Thomson Reuters StreetEvents) -10.55%
11:15AM
10:02AM
Feb-06-24 06:30PM
05:35PM
04:35PM
04:02PM
Feb-05-24 08:00AM
Feb-04-24 06:56AM
Feb-01-24 06:55AM
Jan-30-24 10:00AM
Jan-26-24 08:00AM
Jan-24-24 10:15AM
Jan-19-24 01:12AM
Jan-10-24 10:45AM
Jan-09-24 10:39AM
08:00AM
Jan-08-24 08:00AM
Jan-05-24 01:07PM
Dec-29-23 09:00AM
Dec-28-23 08:00AM
Dec-27-23 06:26PM
05:05AM
Dec-21-23 10:30PM
Dec-18-23 08:00AM
Dec-07-23 11:30AM
06:08AM
Nov-30-23 11:20AM
Nov-14-23 03:58PM
08:00AM
Nov-11-23 01:34PM
Nov-09-23 12:41PM
Nov-08-23 05:52PM
07:30AM
Nov-07-23 04:03PM
Nov-01-23 08:00AM
Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ebeling Philip Officer Sep 11 '24 Proposed Sale 247.28 5,453 1,348,445 Sep 11 06:01 PM McCormick Shawn Director Sep 09 '24 Sale 220.00 800 176,000 23,140 Sep 11 05:02 PM Rondoni John Chief Technology Officer Sep 09 '24 Sale 215.00 31 6,665 11,348 Sep 11 05:01 PM SHAWN T MCCORMICK Director Sep 09 '24 Proposed Sale 220.00 800 176,000 Sep 09 04:09 PM JOHN RONDONI Officer Sep 09 '24 Proposed Sale 215.00 31 6,665 Sep 09 04:08 PM Rondoni John Chief Technology Officer Aug 22 '24 Option Exercise 71.00 5,000 355,000 16,379 Aug 23 04:09 PM Rondoni John Chief Technology Officer Aug 22 '24 Sale 189.83 5,000 949,143 11,379 Aug 23 04:09 PM JOHN RONDONI Officer Aug 22 '24 Proposed Sale 189.82 5,000 949,100 Aug 22 04:22 PM Ban Randy Chief Commercial Officer Aug 15 '24 Option Exercise 42.15 16,139 680,259 19,195 Aug 19 08:14 PM Ban Randy Chief Commercial Officer Aug 16 '24 Option Exercise 42.15 4,861 204,891 7,917 Aug 19 08:14 PM Ban Randy Chief Commercial Officer Aug 15 '24 Sale 193.10 16,139 3,116,397 3,056 Aug 19 08:14 PM Ban Randy Chief Commercial Officer Aug 16 '24 Sale 188.55 4,861 916,549 3,056 Aug 19 08:14 PM RANDALL A BAN Officer Aug 16 '24 Proposed Sale 188.55 4,861 916,560 Aug 16 04:34 PM Ebeling Philip Officer Aug 15 '24 Proposed Sale 194.84 43,901 8,553,615 Aug 15 05:36 PM McCormick Shawn Director Aug 14 '24 Option Exercise 0.94 8,537 8,025 23,940 Aug 15 04:19 PM RANDALL A BAN Officer Aug 15 '24 Proposed Sale 193.10 16,139 3,116,380 Aug 15 04:13 PM Ebeling Philip Officer Aug 14 '24 Proposed Sale 190.03 4,596 873,393 Aug 14 04:50 PM Griffin Jerry C Director Jul 26 '24 Proposed Sale 126.53 5,952 753,086 Jul 26 05:02 PM McCormick Shawn Director May 10 '24 Option Exercise 0.94 2,500 2,350 15,403 May 13 04:30 PM NELSON MARILYN C Director Apr 29 '24 Option Exercise 240.68 1,175 282,799 35,620 May 01 04:01 PM Buchholz Richard Chief Financial Officer Apr 17 '24 Sale 230.03 15,000 3,450,450 28,271 Apr 18 04:44 PM Herbert Timothy P. CEO and President Apr 01 '24 Sale 205.09 40,000 8,203,581 63,658 Apr 03 07:44 PM Griffin Jerry C Director Apr 01 '24 Option Exercise 16.00 296 4,736 10,932 Apr 03 04:55 PM Griffin Jerry C Director Apr 01 '24 Sale 213.99 32 6,848 10,900 Apr 03 04:55 PM NELSON MARILYN C Director Apr 01 '24 Option Exercise 16.00 3,273 52,368 34,338 Apr 02 08:29 PM NELSON MARILYN C Director Mar 27 '24 Option Exercise 90.85 3,243 294,633 31,065 Mar 29 04:49 PM Griffin Jerry C Director Mar 25 '24 Option Exercise 16.00 1,000 16,000 11,190 Mar 27 04:01 PM Griffin Jerry C Director Mar 25 '24 Sale 197.81 554 109,587 10,636 Mar 27 04:01 PM Rondoni John Chief Technology Officer Mar 22 '24 Sale 194.40 4,387 852,849 11,270 Mar 26 08:23 PM Griffin Jerry C Director Mar 18 '24 Option Exercise 16.00 1,000 16,000 10,744 Mar 20 05:51 PM Griffin Jerry C Director Mar 18 '24 Sale 193.53 554 107,216 10,190 Mar 20 05:51 PM Griffin Jerry C Director Mar 11 '24 Option Exercise 16.00 1,000 16,000 10,298 Mar 13 09:21 PM Griffin Jerry C Director Mar 11 '24 Sale 198.05 554 109,720 9,744 Mar 13 09:21 PM Griffin Jerry C Director Mar 01 '24 Option Exercise 16.00 1,000 16,000 9,852 Mar 05 05:08 PM Griffin Jerry C Director Mar 01 '24 Sale 179.44 554 99,410 8,298 Mar 05 05:08 PM NELSON MARILYN C Director Mar 01 '24 Option Exercise 0.94 2,555 2,402 27,822 Mar 05 05:06 PM Rondoni John Chief Technology Officer Feb 29 '24 Sale 179.25 8,605 1,542,441 15,657 Mar 04 06:21 PM Ban Randy Chief Commercial Officer Feb 27 '24 Option Exercise 42.15 3,060 128,979 6,089 Feb 27 08:39 PM Ban Randy Chief Commercial Officer Feb 23 '24 Option Exercise 4.11 12,230 50,234 15,259 Feb 27 08:39 PM Ban Randy Chief Commercial Officer Feb 23 '24 Sale 185.37 12,230 2,267,075 3,029 Feb 27 08:39 PM Ban Randy Chief Commercial Officer Feb 27 '24 Sale 182.01 3,060 556,951 3,029 Feb 27 08:39 PM Rondoni John Chief Technology Officer Feb 15 '24 Option Exercise 2.07 8,000 16,560 24,262 Feb 16 04:05 PM NELSON MARILYN C Director Feb 09 '24 Option Exercise 0.94 4,000 3,760 25,267 Feb 13 04:01 PM Jandrich Steven VP, Human Resources Jan 30 '24 Option Exercise 0.94 16,225 15,252 23,096 Jan 31 08:40 PM Sparks Charisse Y Chief Medical Officer Oct 12 '23 Buy 153.50 100 15,350 998 Jan 24 04:32 PM NELSON MARILYN C Director Oct 17 '23 Option Exercise 0.94 2,000 1,880 21,100 Oct 17 07:52 PM Herbert Timothy P. CEO and President Oct 12 '23 Option Exercise 5.43 208,036 1,128,811 203,691 Oct 16 07:53 PM NELSON MARILYN C Director Sep 21 '23 Option Exercise 0.94 2,000 1,880 18,959 Sep 25 06:30 PM
Index RUT
P/E -
EPS (ttm) -2.12
Insider Own 5.66%
Shs Outstand 36.36M
Perf Week 1.04%
Market Cap 218.09M
Forward P/E -
EPS next Y -2.63
Insider Trans 0.00%
Shs Float 35.17M
Perf Month 7.14%
Income -77.44M
PEG -
EPS next Q -0.82
Inst Own 100.16%
Short Float 8.48%
Perf Quarter -33.75%
Sales 426.10M
P/S 0.51
EPS this Y -8.15%
Inst Trans -1.51%
Short Ratio 4.34
Perf Half Y -57.76%
Book/sh 7.37
P/B 0.79
EPS next Y 5.14%
ROA -13.21%
Short Interest 2.98M
Perf Year -70.78%
Cash/sh 7.34
P/C 0.80
EPS next 5Y -
ROE -27.22%
52W Range 4.38 - 22.64
Perf YTD -72.82%
Dividend Est. -
P/FCF -
EPS past 5Y -9.37%
ROI -16.18%
52W High -74.16%
Beta 0.94
Dividend TTM -
Quick Ratio 3.53
Sales past 5Y 2.01%
Gross Margin 64.91%
52W Low 33.50%
ATR (14) 0.46
Dividend Ex-Date -
Current Ratio 4.77
EPS Y/Y TTM -2494.48%
Oper. Margin -22.03%
RSI (14) 49.14
Volatility 5.87% 7.15%
Employees 1215
Debt/Eq 0.88
Sales Y/Y TTM 1.59%
Profit Margin -18.18%
Recom 3.53
Target Price 7.32
Option/Short Yes / Yes
LT Debt/Eq 0.75
EPS Q/Q 23.00%
Payout -
Rel Volume 2.29
Prev Close 5.85
Sales Surprise -2.76%
EPS Surprise 23.99%
Sales Q/Q -4.27%
Earnings Aug 06 AMC
Avg Volume 686.67K
Price 5.85
SMA20 5.34%
SMA50 -16.67%
SMA200 -52.92%
Trades
Volume 1,570,044
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-09-24 Upgrade
Citigroup
Sell → Neutral
Aug-08-24 Upgrade
Wolfe Research
Underperform → Peer Perform
Aug-07-24 Downgrade
Wells Fargo
Equal Weight → Underweight
$13 → $5.50
Aug-07-24 Downgrade
JP Morgan
Neutral → Underweight
Aug-07-24 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
May-22-24 Downgrade
Citigroup
Neutral → Sell
$13.50 → $9
Feb-22-24 Downgrade
Oppenheimer
Outperform → Perform
Jan-12-24 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$23 → $20
Dec-21-23 Downgrade
Canaccord Genuity
Buy → Hold
$23
Jul-19-23 Initiated
Robert W. Baird
Neutral
$26
May-31-23 Initiated
RBC Capital Mkts
Outperform
$40
May-15-23 Upgrade
Oppenheimer
Perform → Outperform
$40
Apr-14-23 Initiated
Mizuho
Neutral
$40
Jan-17-23 Downgrade
Citigroup
Buy → Neutral
$40
Jan-06-23 Downgrade
Piper Sandler
Neutral → Underweight
$42 → $38
Dec-20-22 Upgrade
Canaccord Genuity
Hold → Buy
$41 → $67
Dec-12-22 Downgrade
Wells Fargo
Overweight → Equal Weight
$66 → $43
Oct-12-22 Initiated
Jefferies
Underperform
$31
May-05-22 Upgrade
Citigroup
Neutral → Buy
$78
Apr-13-22 Resumed
Truist
Hold
$72 → $80
Show Previous Ratings
Sep-19-24 04:30PM
Sep-12-24 01:20AM
Aug-28-24 04:15PM
Aug-20-24 01:04PM
Aug-14-24 04:30PM
(PR Newswire) -6.18%
+12.21%
05:13PM
Loading…
Aug-13-24 05:13PM
Aug-09-24 08:22AM
Aug-08-24 01:38AM
Aug-07-24 01:01PM
Aug-06-24 05:55PM
04:52PM
(Associated Press Finance)
04:05PM
Jul-11-24 04:15PM
01:58PM
Jul-09-24 04:15PM
(PR Newswire) -9.08%
+5.26%
08:30AM
Loading…
Jun-28-24 08:30AM
Jun-11-24 04:15PM
Jun-06-24 11:31AM
Jun-04-24 12:37PM
Jun-03-24 04:13AM
May-24-24 04:15PM
May-09-24 04:05PM
May-08-24 02:57PM
02:07PM
12:14PM
12:12PM
11:03AM
06:56AM
(Thomson Reuters StreetEvents)
03:50AM
May-07-24 09:56PM
05:30PM
Loading…
05:30PM
04:27PM
(Associated Press Finance)
04:05PM
Apr-17-24 08:30AM
Mar-21-24 12:35PM
Feb-29-24 07:29AM
Feb-28-24 04:10PM
Feb-22-24 06:21PM
11:20AM
10:50AM
06:40AM
(Thomson Reuters StreetEvents)
Feb-21-24 05:20PM
04:43PM
04:21PM
(Associated Press Finance)
04:06PM
04:05PM
Feb-14-24 10:00AM
Feb-01-24 04:30PM
Jan-29-24 04:30PM
Jan-22-24 05:00AM
Jan-19-24 10:48AM
Jan-18-24 04:15PM
Jan-17-24 04:15PM
Jan-14-24 05:28PM
Jan-10-24 09:41AM
12:43AM
Jan-09-24 08:30AM
Jan-04-24 04:15PM
Dec-26-23 11:45AM
Dec-12-23 06:56AM
Dec-04-23 06:07AM
Dec-01-23 11:31AM
11:16AM
Nov-30-23 05:19PM
Nov-23-23 09:55AM
Nov-21-23 09:14AM
Nov-20-23 07:00AM
Nov-02-23 06:33PM
12:16PM
08:33AM
(Thomson Reuters StreetEvents)
Nov-01-23 07:29PM
04:26PM
(Associated Press Finance)
04:01PM
Oct-25-23 10:02AM
Oct-04-23 07:00AM
Sep-18-23 07:00AM
02:23AM
Aug-23-23 07:00AM
Aug-18-23 01:01PM
Aug-16-23 07:00AM
Aug-15-23 10:32AM
Aug-10-23 04:52AM
Aug-02-23 03:40PM
11:28AM
Aug-01-23 05:45PM
04:40PM
04:03PM
Jul-31-23 09:43AM
Jul-27-23 09:15AM
Jul-13-23 07:00AM
Jul-12-23 07:00AM
Jun-27-23 07:00AM
Jun-23-23 07:00AM
Jun-19-23 10:27AM
Jun-07-23 08:04AM
Jun-05-23 04:05PM
Jun-02-23 11:31AM
May-22-23 07:00AM
May-18-23 06:52AM
Apr-27-23 04:05PM
Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite